Recommanded Tools
AbSeek™ encompasses antibody sequence analysis, structure and function prediction, lead optimization, de novo generation, and visualization, among others, covering all stages of antibody discovery and engineering from screening to optimization for efficient innovation.
Free Tools Limited Time
Sequence Analysis
Function Prediction
Lead Optimization
Structure Prediction
New
Molecule Generation

Features & Advantages
Integration
Combines multiple algorithms to provide a one-stop service that meets all needs in antibody discovery and engineering.
Expertise
Tailors UI and data visualization methods based on the characteristics of antibody data for better suitability.
Advancement
Continuously updates cutting-edge AI algorithms to ensure the platform's timeliness and advancement.
Data Security
Committed to providing users with a secure and reliable data environment, alleviating concerns about data leakage.
News
Cyagen Talk|AI-Powered Antibody Discovery: From HUGO-Ab Mice to Predictive Models
AbSeek™: Intelligent Antibody Computational Platform
2025-03-19
More >>【Frontier Express】Antibodies | Antibody-Based Continuation and Maintenance Strategies After Chemotherapy in HER2-Positive Metastatic Breast Cancer
2026-04-29
【Frontier Express】Antibodies | Brain-Targeted Delivery for Alzheimer's Disease: Antibody Fusion Therapies Focused on Transferrin Receptor
2026-04-29
【Frontier Express】Signal Transduction and Targeted Therapy | A single-arm phase II study of abexinostat as a histone deacetylase inhibitor in relapsed/refractory follicular lymphoma
2026-04-29
【Frontier Express】Nature Immunology | A Mass Cytometry Method Pairing T Cell Receptor and Differentiation State Analysis
2026-04-29
【Frontier Express】Nature Medicine | Study on the Application of CD73 Inhibitor Quemliclustat Combined with Chemotherapy in Metastatic Pancreatic Cancer
2026-04-27
【Frontier Express】Journal of Clinical Oncology | CD19/CD22 Dual-Targeted Sequential Immunotherapy in Elderly Patients with B-ALL
2026-04-27
【Frontier Express】Nature Medicine | Randomized Phase 2 TACITO Trial of FMT Combined with Pembrolizumab and Axitinib in Metastatic Renal Cell Carcinoma
2026-04-26






